Corvus Pharmaceuticals Inc（CRVS）の株式分析CRVSCorvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of ITK inhibition as a new approach to immunotherapy for a range of cancer and immune diseases. Its lead product candidate is soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. ITK, an enzyme that functions in T cell signaling and differentiation, is expressed predominantly in T cells. Its second product candidate, ciforadenant, is an oral, small molecule antagonist of the A2A receptor for adenosine designed to disable a tumor’s ability to subvert attack by the immune system by blocking the binding of immunosuppressive adenosine in the tumor microenvironment to the A2A receptor. The Company’s third product candidate is mupadolimab, a humanized monoclonal antibody that is designed to react with a specific site on CD73. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Corvus Pharmaceuticals Inc is currently trading at $9.52, which is significantly below its 200-day simple moving average of $14.277, indicating a bearish trend. The RSI is at 29.901, suggesting that the stock is oversold, but this could also indicate continued downward pressure. The company has a forward P/E of 0, reflecting uncertainty in future earnings, and a recent 5-day change of -9.51% shows a decline in momentum. However, insider David Scott Moore's recent purchase of shares indicates some confidence in the company's future, despite ongoing losses, with a net income of -$17,959,000 in Q2 2026. Given these factors, it may be prudent to hold off on buying until clearer positive signals emerge.

6 analysts cover CRVS: 5 rate it Buy, 1 Hold and 0 Sell. The average price target is 13.33.